Cargando…

Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial

Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dörr, Jan, Wernecke, Klaus-Dieter, Würfel, Jens, Bellmann-Strobl, Judith, Siffrin, Volker, Sättler, Muriel B., Simons, Mikael, Linsa, Andreas, Tumani, Hayrettin, Paul, Friedemann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190842/ https://www.ncbi.nlm.nih.gov/pubmed/30356868 http://dx.doi.org/10.3389/fneur.2018.00842

Ejemplares similares

Vitamin D and Disease Severity in Multiple Sclerosis—Baseline Data From the Randomized Controlled Trial (EVIDIMS)
por: Bäcker-Koduah, Priscilla, et al.
Publicado: (2020)

Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis: A Randomized, Placebo-Controlled Trial
por: Bellmann-Strobl, Judith, et al.
Publicado: (2021)

Retinal Thickness Analysis in Progressive Multiple Sclerosis Patients Treated With Epigallocatechin Gallate: Optical Coherence Tomography Results From the SUPREMES Study
por: Klumbies, Katharina, et al.
Publicado: (2021)

Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial
por: Rust, Rebekka, et al.
Publicado: (2021)

Low contrast visual acuity testing is associated with cognitive performance in multiple sclerosis: a cross-sectional pilot study
por: Wieder, Laura, et al.
Publicado: (2013)

Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
por: Paul, Friedemann, et al.
Publicado: (2008)

Standardization of T1w/T2w Ratio Improves Detection of Tissue Damage in Multiple Sclerosis
por: Cooper, Graham, et al.
Publicado: (2019)

Association Between Fatigue and Motor Exertion in Patients With Multiple Sclerosis—a Prospective Study
por: Drebinger, Daniel, et al.
Publicado: (2020)

Neural Processes of Psychological Stress and Relaxation Predict the Future Evolution of Quality of Life in Multiple Sclerosis
por: Meyer-Arndt, Lil, et al.
Publicado: (2021)

Association of Retinal and Macular Damage with Brain Atrophy in Multiple Sclerosis
por: Dörr, Jan, et al.
Publicado: (2011)

Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells
por: Schwichtenberg, Svenja C., et al.
Publicado: (2021)

Altered Coupling of Psychological Relaxation and Regional Volume of Brain Reward Areas in Multiple Sclerosis
por: Wakonig, Katharina, et al.
Publicado: (2020)

Flupirtine: Clinical pharmacology
por: Harish, S, et al.
Publicado: (2012)

High-dose vitamin D supplementation in multiple sclerosis – results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial
por: Dörr, Jan, et al.
Publicado: (2020)

Modifications of the Triaminoaryl Metabophore of Flupirtine and Retigabine Aimed at Avoiding Quinone Diimine Formation
por: Wurm, Konrad W., et al.
Publicado: (2022)

Clinical associations and characteristics of the polyspecific intrathecal immune response in elderly patients with non-multiple sclerosis chronic autoimmune-inflammatory neurological diseases – a retrospective cross-sectional study
por: Brauchle, Felix, et al.
Publicado: (2023)

Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIOMS): study protocol for a randomized controlled trial
por: Rosche, Berit, et al.
Publicado: (2013)

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
por: Abdelhak, Ahmed, et al.
Publicado: (2019)

A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
por: Huss, André, et al.
Publicado: (2020)

Effect of vitamin D supplementation on N‐glycan branching and cellular immunophenotypes in MS
por: Bäcker‐Koduah, Priscilla, et al.
Publicado: (2020)

Differences in Advanced Magnetic Resonance Imaging in MOG-IgG and AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders: A Comparative Study
por: Schmidt, Felix A., et al.
Publicado: (2020)

CSF oligoclonal IgG bands are not associated with ALS progression and prognosis
por: Klose, Veronika, et al.
Publicado: (2023)

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle
por: Abdelhak, Ahmed, et al.
Publicado: (2017)

Inhibition of Spontaneous Contractility of Isolated Caprine Ureter by Flupirtine
por: Naik, Girish S, et al.
Publicado: (2018)

Flupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses
por: Makoukji, Joelle, et al.
Publicado: (2018)

Exogenous Flupirtine as Potential Treatment for CLN3 Disease
por: Maalouf, Katia, et al.
Publicado: (2020)

Flupirtine in the Management of Taxane-induced Pain in Cancer Patients
por: Paul, Anusha, et al.
Publicado: (2022)

Slower progression of amyotrophic lateral sclerosis with external application of a Chinese herbal plaster–The randomized, placebo-controlled triple-blinded ALS-CHEPLA trial
por: Schröder, Sven, et al.
Publicado: (2022)

MRI Markers and Functional Performance in Patients With CIS and MS: A Cross-Sectional Study
por: Rasche, Ludwig, et al.
Publicado: (2018)

Sleep Disorders Reduce Health-Related Quality of Life in Multiple Sclerosis (Nottingham Health Profile Data in Patients with Multiple Sclerosis)
por: Veauthier, Christian, et al.
Publicado: (2015)

Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
por: Kuchling, Joseph, et al.
Publicado: (2020)

The TRACK-MS Test Battery: A Very Brief Tool to Track Multiple Sclerosis-Related Cognitive Impairment
por: Taranu, Daniela, et al.
Publicado: (2022)

MRI Pattern Recognition in Multiple Sclerosis Normal-Appearing Brain Areas
por: Weygandt, Martin, et al.
Publicado: (2011)

Effect of flupirtine on the growth and viability of U373 malignant glioma cells
por: Panchanathan, Elango, et al.
Publicado: (2013)

Antiepileptic activity and subtype-selective action of flupirtine at GABA(A) receptors
por: Bajrić, Mirnes, et al.
Publicado: (2012)

Role of flupirtine as a preemptive analgesic in patients undergoing laparoscopic cholecystectomy
por: Yadav, Ghanshyam, et al.
Publicado: (2015)

Role of flupirtine in reducing preoperative anxiety of patients undergoing craniotomy procedure
por: Yadav, Ghanshyam, et al.
Publicado: (2017)

Efficacy of flupirtine for postoperative pain: A systematic review and meta-analysis
por: Dey, Samarjit, et al.
Publicado: (2023)

Poor Sleep in Multiple Sclerosis Correlates with Beck Depression Inventory Values, but Not with Polysomnographic Data
por: Veauthier, Christian, et al.
Publicado: (2016)

Inflammatory Cytokines Associated with Multiple Sclerosis Directly Induce Alterations of Neuronal Cytoarchitecture in Human Neurons
por: Meyer-Arndt, Lil, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o9p5qd38a10jlo7l37l9q2d1a8